Bayer HealthCare AG is subsidiary of Bayer AG group, which has three major sub-groups-Bayer HealthCare, Bayer CropScience and Bayer Material Science. Bayer HealthCare AG has further four divisions – Animal Health, Consumer Care, Medical Care and Pharmaceuticals. Pharmaceutical Division is the largest entity of Bayer HealthCare and is known as Bayer Pharma AG and employs nearly 38000 employees worldwide and contributes to approx. €11 billion in annual revenue.
Bayer AG is a Global Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. Since 2003, Bayer AG acts as a holding company of Bayer Group of companies.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Copanlisib / BAY 80-6946 | PI3K | III | Non-Hodgkin Lymphoma | NCT04685915 | Small Molecule |
| II | Chronic Lymphocytic Leukemia | NCT04685915 | |||
| II | Diffuse Large B-Cell Lymphoma | NCT02391116 | |||
| II | Biliary Carcinoma | NCT02631590 | |||
| Gall Bladder Carcinoma | |||||
| Cholangiocarcinoma | |||||
| Gastrointestinal Tumor | |||||
| I/II | Non-small Cell Lung Cancer | NCT03735628 | |||
| Head and Neck Cancer | |||||
| Hepatocellular Carcinoma | |||||
| Vitrakvi® / Larotrectinib / BAY2757556 | TRK | II | Recurrent Solid Tumors | NCT03213704 | Small Molecule |
| Non-Hodgkin Lymphoma | |||||
| I | High Grade Glioma | NCT04655404 | |||
| Rogaratinib / BAY 1163877 | FGFR | II/III | Metastatic Urothelial Carcinoma | NCT03410693 | Small Molecule |
| II | Non-small Cell Lung Cancer | NCT03762122 | |||
| II | Gastrointestinal Stromal Tumor | NCT04595747 | |||
| Recurrent Sarcoma | |||||
| Anetumab ravtansine | Mesothelin | II | Pancreatic Cancer | NCT03023722 | Antibody Drug Conjugate |
| II | Pleural Malignant Mesothelioma | NCT02610140 | |||
| I | Ovarian Neoplasms | NCT02751918 | |||
| Selitrectinib /BAY2731954 / Loxo-195 | TRK | I/II | Advance Solid Tumors | NCT03215511 | Small Molecule |
| BAY2287411 | Mesothelin | I | Recurrent Mesothelioma | NCT03507452 | Radiopharmaceutical |
| Ovarian Cancer | |||||
| Advanced Pancreatic Adenocarcinoma | |||||
| BAY2701439 | HER2 | I | HER2+ Advanced Solid Tumors | NCT04147819 | Radiopharmaceutical |
| BAY 2315497 | PSMA | I | Prostate Cancer (mCRPC) | NCT03724747 | Radiopharmaceutical |
| BAY 2416964 | AhRi | I | Advanced Solid Tumors | NCT04069026 | Small Molecule |
| BAY1834942 | CEACAM6 | I | Advanced CEACAM6+ Solid Tumors | NCT03596372 | Monoclonal Antibody |
| BAY 1905254 | ILDR2 | I | Advanced Solid Tumor | NCT03666273 | Monoclonal Antibody |
| BAY1895344 | ATR | I | Advanced Solid Tumors | NCT03188965 | Small Molecule |
| Lymphomas |
Bayer’s Active Oncology Pipeline Drug Description
- Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B-cells.
- Larotrectinib, a highly selective, first-in-class TRK inhibitor, granted accelerated FDA approval for for the treatment of TRK fusion cancer.
- Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are genomic rearrangements containing the kinase domain of one of three tropomyosin receptor kinases (TRK) and a dimerization domain contributed by another gene, generating fusion proteins, which are oncogenic drivers, targetable with TRK inhibitors.
- Rogaratinib (BAY 1163877) is a small molecule novel pan‐FGFR inhibitor designed to reversibly occupy the ATP‐binding pocket of the kinase domain of FGFRs 1–4.
- Fibroblast growth factor signaling has been implicated in the development of various cancers, including squamous cell lung cancer, squamous cell head and neck carcinoma, colorectal and bladder cancer.
- Anetumab ravtansine is a novel mesothelin-targeting antibody-drug conjugate consisting of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4 via a disulfide-containing linker.
- Selitrectinib (formerly LOXO 195) is an oral selective tropomyosin-related-kinase (TRK) inhibitor, for the treatment of neurotrophic tyrosine kinase (NTRK) fusion solid tumors.
- BAY 2701439 is a radioimmunoconjugate consisting of a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 conjugated with thorium-227 which emits radiation (a lot of energy that moves from one place to another with damaging effects). The alpha particles are expected to damage the tumor cells and cause them to die, but spare surrounding tissue as alpha particles travel only very short distances in the body.
- BAY 2315497, is a thorium-227 labeled immuno-conjugate, specific for the prostate-specific membrane antigen (PSMA), which will be evaluated in patients with metastatic castration resistant prostate cancer.
- BAY2416964 is a small molecule which blocks the Aryl Hydrocarbon Receptor (a protein involved in immune cell reaction to tumor cells) allowing the body to use its immune response against the tumor cells.
- BAY 1834942 is an immunotherapeutic antibody blocking the novel immune checkpoint regulator CEACAM6 (CD66c).
- BAY 1905254 a novel immune checkpoint inhibitor for cancer immunotherapy targeting the immunoglobulin-like domain containing receptor 2 (ILDR2).
- BAY1895344 is an oral ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor.
Page 2 of 2
